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Abstract
Background: Next-generation amplicon sequencing enables high-throughput genetic diagnostics, sequencing 
multiple genes in several patients together in one sequencing run. Currently, no open-source out-of-the-box software 
solution exists that reliably reports detected genetic variations and that can be used to improve future sequencing 
effectiveness by analyzing the PCR reactions.
Results: We developed an integrated database oriented software pipeline for analysis of 454/Roche GS-FLX amplicon 
resequencing experiments using Perl and a relational database. The pipeline enables variation detection, variation 
detection validation, and advanced data analysis, which provides information that can be used to optimize PCR 
efficiency using traditional means. The modular approach enables customization of the pipeline where needed and 
allows researchers to adopt their analysis pipeline to their experiments. Clear documentation and training data is 
available to test and validate the pipeline prior to using it on real sequencing data.
Conclusions: We designed an open-source database oriented pipeline that enables advanced analysis of 454/Roche 
GS-FLX amplicon resequencing experiments using SQL-statements. This modular database approach allows easy 
coupling with other pipeline modules such as variant interpretation or a LIMS system. There is also a set of standard 
reporting scripts available.
Background
Recent DNA sequencing technology, the so-called next-
generation sequencing (NGS) technology, enables
researchers to read a number of DNA sequences that is
several orders of magnitudes bigger and at a cost that is
several orders of magnitude smaller than the previous
generation DNA sequencing technologies. The cost of
determining the human genome was estimated at $2.7
billion for the IHGSC genome and at $300 million for the
Celera genome. Recently several human genomes were
sequenced in about 1.5 months at a cost that is around
$1.5 million [1,2].
Large-scale parallel pyrosequencing from 454/Roche
generates hundreds of thousands sequenced DNA reads
within a matter of hours [3]. The latest version of the
sequencing technology (Titanium) enables a throughput
of 0.4-0.6 gigabases per 10 h run [4]. The amount of data
to be analyzed keeps growing at an increasing speed.
Other NGS platforms such as Illumina's Genome Ana-
lyzer (San Diego, CA, USA), Applied Biosystems' SOLiD
(Foster City, CA, USA) and Helicos' HeliScope (Cam-
bridge, MA, USA) generate more than 10 gigabases in a
single multi-day run. It is estimated that by 2012 genome
centres around the world will generate more data per year
than the expected 15 petabytes per year that is produced
by CERN's Large Hadron Collider [5].
Sequencing researchers agree that data-analysis of NGS
projects is the biggest challenge to make the technology
accessible for biologists around the world. The cost of
sequencing might go as low as $1,000 per human
genome, but it will still be a lost investment if the gener-
ated data cannot be adequately analyzed. Especially
sequencing platforms with a very high throughput of read
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lengths as short as 35-40 nucleotides face challenges for
genome assembly and annotation [6].
Nevertheless, NGS is expected to have an enormous
impact on diagnostics and SNP discovery [7], provided
there are tools available that make variant detection and
interpretation of the sequenced data straightforward and
automated. A good step towards standardization and data
uniformity, especially in the short-read field, was taken
with the development of the SAM/BAM format [8]. This
format is currently supported by BWA [9] and Bowtie
[10], but is not supported by long-read (typically 454 GS-
FLX data) mappers such as BLAT [11]. However, with the
recent release of BWA-SW [12] one might expect a more
broad transition of long-read NGS towards SAM/BAM
pipelines.
There are already some tools available to analyze 454
GS-FLX experiments, but mostly with a limited analysis
spectrum. Most of the present tools are designed to do a
specific task, and rarely offer broad spectrum analysis.
The few integrated analysis tools offering broad spectrum
analysis available are commercial packages (such as
CLCbio Genomics Workbench, Genomatix or Next-
GENe).
Mosaik [13] for example is one of the few broader anal-
ysis packages available and has cross-platform features
which makes it indeed easy to work with. Unfortunately it
lacks some additional analysing possibilities besides map-
ping and assembly that are useful in amplicon resequenc-
ing based diagnostics (for example coverage per amplicon
and per patient or calculation of primer dimer frequen-
cies).
Roche's Amplicon Variant Analyzer (AVA) software is
specifically designed for analysis of amplicon resequenc-
ing experiments and is user-friendly but has some limita-
tions. Advanced coverage analysis is of paramount
importance in a diagnostic setting but is lacking in AVA.
Data storage is also an issue using AVA as data is not
stored in a structured way (i.e. flat files instead of storage
in a database).
In this paper we describe an open-source database ori-
ented pipeline that is capable of analyzing a single GS-
FLX amplicon resequencing run automatically from
receiving the raw data to generating custom (variation)
reports within one day. Using the database approach, the
pipeline is capable of analyzing a set of runs together in a
meta-analysis. While sequence variations can be assessed
using this pipeline, it also allows researchers in diagnostic
labs to extract additional information (e.g. frequency of
primer dimers). This data can then be used to optimize
the amplicon PCR reactions and general sequencing set-
tings to improve future sequencing runs. The pipeline, a
manual, a testing dataset, and example reports are avail-
able on the web at http://athos.ugent.be/VIP_pipeline.
Implementation
The Variant Identification Pipeline (VIP) is developed in
a modular way so that each module can run indepen-
dently from another. Each module uses data stored in a
relational database (MySQL) to do its task and stores its
result again in the database (Figure 1). The pipeline is
completely written in Perl and the DBI and DBD::mysql
packages are used for database interactions.
Processing the raw sequence data
The pipeline uses both the FASTA (sequenced reads) and
FASTQ (positional quality scores of the sequenced reads)
files generated by the 454/Roche GS-FLX sequencer as
input and processes the files in a way so that a DNA
sequence is linked to a sequence of quality scores. In a
first step the DNA sequence is trimmed using a variety of
algorithms. The multiplex identifier or MID (a short bar-
code sequence used to label samples/patients when mul-
tiplexing), the linker sequence (used to link the amplicon
primer together with the MID sequence), and the trailing
sequence (residual reverse complements of the MID/
linker at the end of a sequence) are trimmed. The differ-
ent algorithms allow perfect tag sequences to be trimmed
but also tag sequences with sequencing errors.
Trimming the sequences results in more efficient map-
ping in later stages of the pipeline as artificial nucleotide
strings are removed from the sequence before they can
interfere with the mapping process. The combined length
of the MID and linker is often >20 bp and can cause prob-
lems in mapping, especially when amplicons are already
rather short.
Generating the reference amplicons
Both a reference sequence and a list with forward and
reverse primers (in FASTA format) are fed to the ampli-
con generation module. The primer sequences are
detected in the reference sequence and the reference
amplicons are extracted from the reference sequence.
The reference amplicons, primer information, and
genomic reference information are stored in the refer-
ences database.
Mapping the sequenced amplicons
Recently, several fast and elegant mapping algorithms
have been developed such as Bowtie, BWA or SOAP [14].
Unfortunately, these algorithms were developed for
short-read mapping, typically SOLiD or Illumina reads,
and are thus not suitable for mapping of 454/Roche GS-
FLX reads. In the VIP pipeline, sequenced amplicon
sequences (reads) stored in the raw sequences database
are mapped on the reference amplicons using BLAT. The
output is parsed using Perl, the Bio::Tools::BPlite package
and some custom-made Perl modules (included in the
pipeline package).
De Schrijver et al. BMC Bioinformatics 2010, 11:269
http://www.biomedcentral.com/1471-2105/11/269
Page 3 of 12
In amplicon resequencing experiments spanning large
exons, overlapping amplicons are used to cover the exon
completely. Using the amplicon as a reference template
speeds up the mapping process but can cause sequenced
reads to map on multiple, partially overlapping ampli-
cons. This problem is addressed by using the mapping
position on both the reference sequence and the read.
The read should map completely at the beginning of a ref-
erence amplicon to be considered as a correctly mapped
read.
Sequences with a mapped region (including the PCR
primer) shorter than a certain threshold value (default
value is 40 bp) are considered to be too short to be a real
amplicon. The pipeline will actively look for another
Figure 1 Overview of the VIP pipeline. Overview of the Variant Identification Pipeline (black arrows and white text-boxes) and the VIP Validator (grey 
arrows and grey text-boxes). The analysis pipeline consists of 4 modules. 1) Raw sequences are extracted from the FASTA files generated by the GS-
FLX sequencer and processed into sequenced amplicons and additional information. 2a) Reference amplicons are generated using a list of reference 
sequences and the list of primers. 2b) Mapping is carried out with BLAT using the reference amplicons and the sequenced amplicons. Variations are 
detected and stored in the database. 3) The requested reports are generated. The VIP Validator introduces additional variation in the sequence reads 
and reanalyses those sequences to validate the pipeline for that specific variation.
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mapped region (also shorter than the threshold value) in
the sequenced read. When two such regions at both the
start and end of a read are detected, both are stored in the
database flagged as 'short'.
Users who might prefer to map reads genome-wide - to
detect PCR artefacts for example - have the possibility to
map on the entire genome, rather than on reference
amplicons, using the genome-wide reference database
(which is included in the package). Further downstream
processing is the same for both approaches.
Detecting variation in the mapped data
Once the sequenced reads are mapped on the reference
template and the best mapping position is determined,
the possible differences between the sequenced read and
the reference template along with their position relative
to the reference template are determined. The VIP pipe-
line is capable of detecting deletions, insertions and com-
binations of deletions and insertions.
Rather than storing the alignment itself in a database,
the reference amplicon name and the variations are
stored in the database. A small sequence window around
the variation together with the quality score on the posi-
tion of the variation is stored in the database as this data
is used in later stages of the pipeline.
Reporting
Once the processed data is stored in the database, the VIP
pipeline generates eight standard reports that give end-
users ample information to interpret the raw data (Addi-
tional file 1). Each of these reports can be generated inde-
pendently from each other, comes straight from the
database and is completely independent from the raw
sequence files or raw data processing. Hence, any com-
puter that is connected to the database server can gener-
ate its own reports in a short period of time without
having access to the raw data.
Reports are mainly generated using SQL-statements
and the report generating scripts are partially parallelized
using the Perl packages threads and threads::shared. The
report generating scripts are parallelized where possible,
but one should bear in mind that hard disk accessibility
and memory usage are a bigger issue than processing
power when using SQL-statements (Additional file 2).
Estimating the error profile
Detecting variants followed by interpretation is the most
important goal of amplicon resequencing projects. The
mapping step detects variation by using BLAT and stores
the raw variants in the database. These include real vari-
ants but also sequencing errors. When reporting to the
end-user the VIP pipeline is able to discriminate between
sequencing errors and real variants and is optimized to
reduce false negatives which is of crucial importance in a
diagnostic setting.
In theory, genomic variation is homozygous or
heterozygous, thus the frequency of a certain observed
variant in an amplicon has to be 50% or 100% of the total
reads. In practice, this variant frequency can vary due to
sampling variation, sequencing errors, and biological het-
erogeneity. At low coverage, variants can deviate from the
50% or 100% frequency and make discrimination
between homo- and heterozygous variants difficult.
It is known that much of the sequencing errors occur
when the basecaller software has to determine the exact
length of a stretch of the same nucleotides (homopolymer
sequences) [15]. Homopolymer error rates were calcu-
lated by looking for homopolymer stretches and counting
homopolymer associated deletions and insertions.
Although the overall GS-FLX error rate is reported to be
relative low (≈0.035%; data not shown), the homopolymer
related error rate is at a considerable level (≈10% for
homopolymers with length 6 bp and up to 50% for
homopolymers with length 8 bp; data not shown) and
causing difficulties when calling certain variations as a
true variant or a sequencing error [16]. The art of varia-
tion analysis is to pick the true variants from the total
pool of observed variants. Taking all this into account, a
filter was designed that automatically separates sequenc-
ing errors from real variants.
Alignment visualizer
Sometimes, the best way to determine which variants are
real and which are not is by looking directly to how the
reads were aligned to the reference sequence. The VIP
pipeline contains an alignment visualizer that gives a
global overview of how several reads were aligned to a
reference sequence. The visualizer outputs results per
MID/amplicon combination which users can specify. An
example output of the visualizer is given in additional file
3.
The VIP validator
The VIP validator verifies if a certain introduced variant
can be detected by the pipeline in a background of exist-
ing variants and sequencing errors. Variation is intro-
duced in sequenced reads rather than in the reference
template to simulate analysis of real data.
The validator combines the raw sequences database
and the mapped sequences database to retrieve a set of
raw sequences that map on a certain amplicon which
eventually leads to a set of raw sequences associated with
the specific amplicon. These reads already contain
sequencing errors and real variants. The validator intro-
duces a new variation (SNV, deletion, insertion or combi-
nation) at a certain position in a certain amount of
sequences in this set. This variation can be something
random (i.e. a random variant at a random position) or a
predefined variant.
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These variations are introduced with a certain fre-
quency (from 0% to 100%) and with a certain coverage by
introducing it in a random subset of sequences that are
present in the total set of sequences. This way a dataset is
generated as if it has been sequenced.
This newly generated dataset is then fed to the mapping
and variation detection module of the normal analysis
pipeline and the results are further processed in a valida-
tion reporting step (Figure 1).
Results & discussion
The pipeline is designed to process (multiplexed) ampli-
con resequencing experiments, a setup which is becom-
ing frequently present in diagnostic labs (to replace
classic Sanger sequencing) where several genes from sev-
eral patients are tested together in one sequencing run.
The modular approach makes efficient planning possi-
ble. Time-consuming reporting steps can for example be
postponed to a time when there is sufficient server power
available. This is especially interesting when multiple
runs need to be analyzed in a short period of time and
efficient server usage is required.
The database approach makes it possible to easily gen-
erate reports and draw conclusions from a subset of
sequences of a sequencing run or multiple runs together
(Additional file 4). It also prevents the user from losing
data as all the data is centralized in a single location.
Amplicon pools
The performance of the pipeline was initially assessed by
analyzing two BRCA1/2 resequencing experiments (De
Leeneer et al., in preparation). These two runs contained
samples that had been analyzed before using classic HRM
(high resolution melting) and consequently the variants
in the samples were known. Both runs had a similar
experimental design.
A total of 111 amplicons (44 BRCA1, 67 BRCA2) were
equimolarly pooled together per sample (patient). PCR
products of 11 patients (tagged with MIDs) were then
equimolarly pooled together. Amplicon sizes ranged from
136 bp to 435 bp (mean 244 bp). The first run generated
542,532 reads (mean length 244 bp); the second run gen-
erated 261,646 reads (mean length 247 bp).
Processing the raw data
During the trimming step (processing the raw data),
97.37% of the raw sequences were split into MID
sequence, linker sequence, amplicon sequence and trail-
ing sequence. A small fraction of sequences had a start
with too many sequencing errors to determine the cor-
rect MID, and these sequences were consequently not
used in further analyses (but are nevertheless stored in
the raw sequences database). At the moment there is no
straightforward method to split sequences into MID,
linker and amplicon sequence using the AVA software
(AVA only allows MIDs to be split off ), which makes it
difficult to compare the splitting algorithms, but with a
97.37% yield one can assume that few improvements can
be made.
Mapping the reads
BLAT mapped 85.24% of the sequenced reads generated
in the first run and 93.57% of the reads generated in the
second run. Some of the mapped sequences were filtered
out because they map to a reference amplicon in two
pieces with big gap in between and appear to be clear
primer-dimers (the so-called 'short' sequences). 76% of all
the sequences reads mapped correctly and passed filters
in the first run compared to 92% in the second run. The
residual portion of the sequenced reads that did not map
were further investigated and appeared to be PCR arte-
facts such as complex primer dimers. Only 4,653 reads
(completely or partially) mapped outside the target
regions when mapped genome-wide and only 45 of these
mapped completely (i.e. from start to stop) somewhere in
the genome, from which we concluded that the PCR reac-
tions were specific. Coverage per amplicon and per MID
was heterogeneous and between 0 and 5,134 (mean 310)
for run 1, and between 0 and 3,019 (mean 175) for run 2.
This heterogeneity is mainly caused by differences in
PCR efficiency and suboptimal pooling of samples. This
heterogeneity (or 'spread factor') can be lowered by carry-
ing out improved pooling strategies and incorporating
normalization steps (Hellemans et al., in preparation).
Errors in the labwork and/or PCR reactions not working
as expected caused some amplicons to be not covered
(2.98% in the first run, 1.51% in the second run).
Mapping on reference amplicons rather than on a refer-
ence genome certainly improves speed, but is somewhat
discussable because one might miss paralogous amplifi-
cation products. However, in a diagnostic resequencing
setup one is interested in variants in a certain set of genes
or even a certain exon using thoroughly validated PCR
reactions. Paralogous amplification products might
become apparent when mapping genome-wide (and be
absent when mapping only to reference amplicons) but
they would lack diagnostic significance as they give no or
incorrect information on the region that was intended to
be screened. Users should strive to the use of validated
PCR reactions and omitting genome-wide mapping,
rather than mapping genome-wide. Nevertheless, the
genome-wide approach is included in the package for
users desiring to screen for aspecific PCR products.
Calling true variants
The two BRCA1/2 runs contained samples with known
variants (132 distinct sequence variants of which 90 were
deletion/insertion mutations).
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By setting the filters (using the 'generate reports' script)
at the default values one can discriminate between true
variants and sequencing errors. The recommended val-
ues are: variation frequency (>33% and <67%; >0.95%)
and coverage (>20). However, the coverage filter and fre-
quency filter is dynamic and can be changed and exact fil-
ter values can be calculated in function of the desired
detection power (Hellemans et al., in preparation).
It is difficult to reliably design a filter to only filter out
faulty homopolymer variants. Discarding every variation
preceding or following a homopolymeric region is not an
option as real variants can also flank such regions. We
have seen that for homopolymers < 6 bp there is no prob-
lem discriminating between correctly sequenced
homopolymeric stretches and homopolymer related
insertions or deletions (sequencing errors) by using the
quality score (Q). When using the recommended filter
value Q > 30 only a minor fraction of the homopolymer
related sequencing errors pass the filter (homopolymers
< 6 bp). When the stretches are 6 bp long or longer the
distributions of the normal and the mismatch homopoly-
mers start to overlap and even a correctly sequenced base
has a low Q score (figure 2). We recommend to set the
homopolymer filter at 6 bp and keep in mind that no real
variants preceding or following a 6 bp homopolymeric
stretch can reliably be detected using the default filter
values.
In total 97% of all known variants (homozygous and
heterozygous) could be detected (sensitivity). Specificity
(the portion of called variants that actually are real vari-
ants) was 98.5% which means that the false positive rate is
only 1.5%. All non-detected variants were insertions/
deletions in or near homopolymeric regions. We are
aware of the fact that the given numbers may be overfit-
ted to a BRCA1/2 screening, but very similar results were
obtained in other experiments (20 genes, 4 runs) as well
(data not shown).
A comparison of the data pre- and post-filtering is
given in figure 3. The figure clearly shows that the pre-fil-
ter data contains a lot of 'noise'. Post-filter data is concen-
trated around the 50% and 100% level as expected and
allows easy discrimination between heterozygous and
homozygous variants. At higher coverage, the data is con-
centrated in a band which is narrower than the specified
filter settings. This indicates that at higher coverage,
mainly low Q-score variants and homopolymer-related
variants are filtered out.
VIP compared with AVA
The performance of the VIP pipeline was compared with
the performance of the AVA software (2.0.0.0). Reads
from 1 patient (MID1) containing 67 different amplicons
were analyzed in detail. The sample was known to con-
tain 12 variants.
The AVA software does not handle the linker sequence
between the MID adaptor and the PCR primer very well.
The sequence of the MID/Linker combinations (MID1' =
MID1/linker, MID2' = MID2/linker etc.) were used as
new MIDs in AVA to circumvent the inability of AVA to
split off the linker sequences. The AVA analysis was car-
ried out as described in the manufacturer's manual.
The VIP pipeline returned 50 variants compared to the
235 returned by AVA. This is explained by the fact that
the VIP pipeline has an internal filter which filters out any
variant with a frequency lower than 10% and with a cov-
erage of only 1. These variants are considered random
sequence errors.
Setting a minimum frequency filter in AVA to 20%, 33
variants were identified, whereas 14 variants passed the
different filters in the VIP pipeline. The VIP pipeline
picked up all 12 known variants (including 6 difficult
homopolymer related variants) and called only two false
positives, both homopolymer related. The AVA software
on the other hand missed all 6 homopolymer related vari-
ants and called 27 false positives (Table 1). A detailed
overview of all the variants detected by both AVA and
VIP is given in additional file 5.
Additional reports
Besides generating an overview of the variants, the pipe-
line can also generate additional reports which make the
pipeline very useful in a diagnostic setting. All the data is
intelligently stored in a relational database and therefore
custom analyses can be carried out using SQL-statements
in either an SQL browser such as HeidiSQL [17] or by
writing custom scripts in any scripting or programming
language that has the ability to communicate with a
MySQL database.
This database approach allowed optimization of the
laboratory work of the BRCA1/2 sequencing experi-
ments, especially the pre-sequencing PCR reactions.
Using the data from the database, it was possible to detect
which amplicons were underrepresented. It was also clear
that there were a lot of short sequences in the first run.
Run 1 had 8.73% of total reads flagged as 'short sequence',
run 2 had 1.87% of total reads flagged as such. Using this
information, the multiplex reactions were optimized and
an additional length separation was carried out. These
actions improved the efficiency by reducing undesired
by-products and/or primer dimers from 24% to 8% of the
total sequences (Figure 4). It is vital to reduce by-prod-
ucts such as dimers in the early PCR steps as these
shorter sequences get preferentially amplified in the
emulsion PCR and reduce efficiency even more.
There are 8 standard reports integrated in the reporting
module. Each of the reports is described in detail in the
manual and an overview is present in the additional files.
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Validating variation using the VIP Validator
Random variation in the VIP Validator is defined as a ran-
dom error that is introduced with a certain frequency at a
certain position in a set of sequences that map on a ran-
dom reference amplicon. The Validator introduces the
variant into a number of sequences and then verifies in
how many of these sequences this specific variant was
detected at the exact location where it was introduced.
Random variation validation was initially used to opti-
mize and validate the VIP analysis pipeline but has
proven to be an effective instrument to detect problem-
atic amplicons or problematic regions in certain ampli-
cons. There are amplicons for which few variants have
been reported yet, meaning that amplicon resequencing
experiments can unravel new variants. A simulation with
random variations can give a clue about regions where
Figure 2 Influence of quality score (Q) on homopolymer accuracy. Distribution of homopolymer related quality scores (Q score). The normal ho-
mopolymer Q score distribution is determined by making a distribution of the Q score of the homopolymer base; the mismatch homopolymer Q score 
distribution is determined by making a distribution of the Q score of the base preceding a homopolymer related deletion or the Q score of a homopo-
lymer related inserted base. Distributions are shown for homopolymers with length 3, 5, 6 and 7 bp. The grey vertical lines are drawn at a Q score of 
15 and 30. Distributions are based on data from the two BRCA runs.
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Figure 3 Pre and post filtering variants data. Plot of the coverage (times a single sequence is read by the sequencing equipment) and the frequen-
cy of an observed variation. In reality, genomic variation occurs at a frequency of either 50% or 100% of total reads. The top figure is the distribution 
when no filters are applied to discriminate between sequencing errors and real variants; the bottom figure is the distribution where several filters (fre-
quency filter, Q score filter, coverage filter and homopolymer filter) are applied to discriminate the real variations from the sequencing errors. Vertical 
grey line indicates 40 × coverage; horizontal grey lines indicate respectively 33%, 67% and 95% variation frequency.
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Table 1: Comparison of AVA and VIP performance (1 sample, 67 amplicons, 12 known variants)
AVA software VIP pipeline
Total variants (unfiltered) 235 50
'Pass filter' variants 33 14
True variants called 6/12 (50%) 12/12 (100%)
False positives 27/33 (81.2%) 2/14 (14.2%)
False negatives 6/12 (50%) 0/12 (0%)
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accurate variation detection is difficult; for example mul-
tiple variations close to each other or variations in repeti-
tive regions can be problematic for the mapping software.
The Validator does not explain why a certain region
becomes a difficult region to detect variants but informs
about variants that cannot be detected using the pipeline.
Random variation was introduced by choosing a ran-
dom amplicon, a random position, a random variant, a
random frequency, and a random coverage and then
introducing the variant accordingly. This process was
repeated 1000 times.
The ratio between the number of sequences in which a
variation was introduced (the coverage so to speak) and
the number of sequences wherein the variation was
detected is the detection ratio. This ratio is independent
from the frequency by which a variant was introduced.
It is clear that SNV detection with the VIP is no prob-
lem as 100% of the introduced variants can be detected by
Figure 4 Improving future sequencing efficiency using priors sequencing data. Example of the reporting possibilities. Run 1 had many unmap-
pable and short, mapped sequences. Length distribution showed these were mainly 60-120 bp sequences. In Run 2 optimized PCR reactions and an 
additional length separation were carried out prior to the sequencing with a huge reduction (8% vs. 24%) of unmapped and short sequences and thus 
improving the cost-effectiveness.
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the VIP Validator with a sufficiently high detection ratio.
The 67% threshold is considered as sufficiently high
because the detection ratio for a heterozygous variant
would be at least 33.5% and still pass the 33% filter.
Deletions (and insertions) are often not detected using
the newest NGS mapping and variation detection pack-
ages (Additional file 5). The VIP pipeline can detect >99%
of random 3 bp deletions with a detection ratio ≥ 67%.
Determining the location of a gap appears to be relatively
easy. The difficult part of gap detection is determining
the exact length. Results are similar for longer (10 bp)
deletions and insertions (both 3 bp and 10 bp). An over-
view of the detection ratios is given in figure 5.
These observations make it clear that deletions and
insertions can be detected but one should keep in mind
that the exact length of the insertion/deletion that passes
through the filters is not necessarily the real length. This
is one of the drawbacks of needing multiple reads to have
a reliable call for a single nucleotide position. Neverthe-
less, it is detected that something is wrong, which is
Figure 5 The VIP Validator. Detection ratios of 1000 known BRCA1/2 variants, random SNVs, random 3 bp and 10 bp deletions, and random 3 bp 
and 10 bp insertions. The grey horizontal lines indicate 67% detection ratio. The grey vertical lines indicate a 99% cumulative frequency.
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essential in a diagnostic setting. The alignment visualizer
can be a useful resource to manually assess the exact dele-
tion/insertion size.
Rather than using random variation, the VIP Validator
can also use a list of known variations as input. Validating
known variation is the most useful application of the VIP
Validator in a diagnostic setting. It gives an answer to the
question "If variation × is present in an amplicon, would
it then be possible to detect it using the VIP pipeline?".
The answer to this question is objectively addressed using
the detection ratio parameter.
Around 95% of the known BRCA1/2 variants were
detected by the Validator with a detection ratio of 100%
meaning that in every single read (wherein the variant
was introduced) the variant was detected at the correct
position. The other 5% of the variants were detected with
a detection frequency that is lower than 100% but still >
67% (Figure 5).
The VIP Validator can also be used to determine mini-
mal needed coverage in silico. The number of sequences
wherein variation is introduced can be altered and one
can find a minimal coverage that is needed to have a suffi-
ciently high and reproducible detection frequency.
This Validator is useful for pipeline optimization and
determination of the ideal cut-off values. It allows the
end-user to fine-tune the pipeline to its own needs and to
objectively validate the results of a given pipeline modifi-
cation. Moreover, it allows validation of the analysis soft-
ware with respect to the detection of certain variation
screening, which is very important in diagnostics, and it
determines the detection limits of the pipeline, prior to
starting a diagnostic screening.
Conclusions
We have developed an open-source pipeline that is of
great interest for diagnostic resequencing projects. The
AVA software (the standard GS-FLX software package) is
user-friendly and useful in a research setting but not
exactly what is needed in a diagnostic setting. The VIP
pipeline is a fully automated pipeline that enables accu-
rate variant detection, even insertions and deletions, and
can objectively quantify the identification power by using
the Validator. Although the pipeline performs better than
AVA when detecting homopolymer related variants, one
should bear in mind that reliably detecting variants next
to homopolymers will always be an issue, even with high
coverage and 'intelligent' software packages. The VIP
pipeline also allows a degree of flexibility when one wants
to fine-tune its performance, a feature which is lacking in
AVA.
The pipeline also allows optimization of the sample
preparation procedures and amplicon generating PCR
reactions and offers a complete suite of reports that
allows researchers in diagnostic labs to assess the reliabil-
ity of a sequencing run and the detected variants.
The VIP pipeline is under continuous development and
improvement as more and more sequencing data
becomes available to validate and improve the pipeline.
Furthermore, an additional module is in development to
do an automated and integrated interpretation of the
variants that are discovered using both the amplicon and
the genome-wide pipeline.
A package file containing version 1.3 of the pipeline is
added as additional file 6.
Availability and requirements
• Project name: Variant Identification Pipeline
• Project home page: http://athos.ugent.be/
VIP_pipeline
• Operating system(s): Platform independent
• Programming language: Perl
• Other requirements: BLAT, MySQL
• License: GNU LGPL
• Any restrictions to use by non-academics: none
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Additional file 1 Overview of the standard reports that can be gener-
ated using the pipeline. Overview of the standard reports that can be 
generated and the time needed to generate the files.
Additional file 2 Report generation time when using multi-threading. 
Clock time needed to perform a reporting action using SQL statements and 
the effect of using multiple threads. Increasing threads reduces the clock 
time significantly in the beginning, but using more than 7 threads (and thus 
7 cores in the server) has no beneficial effect. Averages and standard devia-
tion shown for 6 repetitions.
Additional file 3 Example output of the alignment visualizer. Screen-
dump of the output generated by the alignment visualizer. Some annota-
tion is added to the figure to explain the format of the output. Bases 
between 56 and 224 are omitted to ease displaying.
Additional file 4 Doing meta-analyses. An example of the possibilities of 
meta-analyses. Three different runs were grouped together in an analysis of 
the average Q score in function of the read position. Data of more than 1 
million reads was used in the analysis.
Additional file 5 AVA compared with the VIP pipeline. An overview of 
the variants detected by both the AVA software and the VIP pipeline. The 
file shows variants that are detected by both AVA and VIP and variants 
detected by only AVA or VIP. The file also shows detection frequencies and 
other parameters calculated by both AVA and VIP.
Additional file 6 The VIP pipeline package. A RAR-file containing the 
pipeline package (version 1.3), the manual and example data.
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